Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi ... Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst Eli Lilly's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a ... of $17.64 billion, a price-to-earnings ratio ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Short interest in Eisai Co Ltd (OTC:ESALF) increased during the last reporting period, rising from 1.32M to 1.48M. This put -% of the company's publicly available shares short. Short interest for ...

Eisai stock plunged 12.9% to 9.25 ... He kept his outperform rating and 303 price target on Biogen stock. The decision is "somewhat surprising" given physicians have become more comfortable ...

STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on AVXL stock, giving a Buy rating on October 18. Soumit Roy has given his ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.